Pharma stocks with swine flu panacea jump

MUMBAI Tue Aug 11, 2009 4:53pm IST

People wearing masks wait in a queue for a H1N1 flu screening at a hospital in New Delhi August 11, 2009. REUTERS/Fayaz Kabli

People wearing masks wait in a queue for a H1N1 flu screening at a hospital in New Delhi August 11, 2009.

Credit: Reuters/Fayaz Kabli

Related Topics

MUMBAI (Reuters) - Shares of Indian drug firms that make the generic version of Roche's Tamiflu, used to treat H1N1 flu, rose 5-19 percent on Tuesday as the death toll from the pandemic in the country rose to eight.

The Health Minister Ghulam Nabi Azad said on Monday more than 850 people had so far tested positive for the virus, with about 340 under treatment and the rest discharged from hospitals.

Ranbaxy Laboratories, Strides Arcolab and Cipla have all expressed readiness to meet the expected demand for oseltamivir, sold under the brand name Tamiflu.

While Ranbaxy, Strides and Natco Pharma rose 5-19 percent, Cipla closed 0.5 percent lower after rising as much as 3.3 percent in the day.

"It is a sentimental impact," said Sarabjit Kour Nangra, vice president-research, pharmaceuticals, at Angel Broking. "This is unlikely to sway too much the profitability picture of these companies."

A dealer, declining to be named, said the shares were unlikely to stay up for more than a couple of days.

The government's plan to stockpile 20 million dosages of Tamiflu drug will benefit Ranbaxy, Cipla, Strides and unlisted Hetero, but will have no significant impact on their earnings, said another pharmaceutical analyst, declining to be named.

Ranbaxy, majority-owned by Japan's Daiichi Sankyo, produces oseltamivir bulk drugs and formulations and can provide close to a million capsules in the next few weeks to the domestic market, Ranbaxy's president Ramesh Adige said in a statement.

The H1N1 virus, commonly known as swine flu, emerged in April in the United States and Mexico, and has spread globally.

The World Health Organisation has said the H1N1 swine flu is unstoppable and has given up on trying to get a precise count of cases.

(For more news on Reuters Money click in.reuters.com/money)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Coal Block Allocation

Coal Block Allocation

Government urges Supreme Court to not cancel some 'illegal' coal mines  Full Article 

Modi in Japan

Modi in Japan

Japan and India agree to boost strategic ties at summit  Full Article 

Basel III Norms

Basel III Norms

RBI amends Basel III guidelines for banks  Full Article 

HSBC PMI

HSBC PMI

Factory activity expands at slower clip in August.  Full Article 

Current Account

Current Account

Balance of payments surplus for third straight quarter  Full Article 

India Infrastructure

India Infrastructure

RBI rule handicaps India's infrastructure hopes  Full Article 

Book Talk

Book Talk

Reema Abbasi and a glimpse of Pakistan’s Hindu past  Full Article 

China Economy

China Economy

Retreat in China's PMIs heightens calls for policy easing.  Full Article 

Managing Share Sales

Managing Share Sales

Govt seeks bids from banks to manage PFC, REC share sales   Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage